Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey

Basit Öğe Kaydı
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.contributor.authorUmit, Elif Gulsum
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorKirkizlar, Hakki Onur
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2024-06-12T10:50:34Z
dc.date.available2024-06-12T10:50:34Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractOBJECTIVE: Invasive fungal infections (IFI) are important and trending causes of mortality in patients with acute leukemia, especially during the remission induction. METHODS: In this study, 225 patients who were diagnosed with acute myeloid leukemia (AML) and undergoing intensive treatment for remission induction were enrolled in a retrospective manner. RESULTS: Within the whole group, which consisted of 225 patients, 90 patients received prophylactic antifungal treatment (PAT) (40%), while 135 patients did not (60%) receive. The mean cost of hospitalization was 9.151,6 (2.872,6-20.483,3) US dollars. Gender distribution and mean ages of groups were similar. One hundred fourteen patients not on PAT (84.4%) and five patients on PAT (5.5%) received intravenous antifungal treatment. Thirty-two of the patients who were not on PAT (23.7%) and 11 of the patients on PAT died during remission induction (12.22%). The mean day of the hospitalization was 22.61 days for the patients on PAT and 33.89 days for the patients who were not on PAT. In patients on PAT, the mean number of transfused platelet units was six (0-9), while 12.51 (4-43) units for patients who were not on PAT. CONCLUSION: In our study, the oral suspension form of posaconazole was observed to be cost-effective to prevent IFI with a significant decrease in mortality during remission induction treatment.en_US
dc.identifier.doi10.14744/nci.2019.89896
dc.identifier.endpage225en_US
dc.identifier.issn2148-4902
dc.identifier.issue3en_US
dc.identifier.pmid32478292en_US
dc.identifier.startpage222en_US
dc.identifier.trdizinid357709en_US
dc.identifier.urihttps://doi.org/10.14744/nci.2019.89896
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/357709
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18056
dc.identifier.volume7en_US
dc.identifier.wosWOS:000534635600004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofNorthern Clinics Of Istanbulen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectInvasive Fungal Infectionen_US
dc.subjectInvasive Fungal-Infectionsen_US
dc.subjectAntifungal Prophylaxisen_US
dc.subjectCost-Effectivenessen_US
dc.subjectPreventionen_US
dc.subjectRecommendationsen_US
dc.subjectUpdateen_US
dc.titleEconomic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu